AcelRx Pharmaceuticals, Inc. ACRX NASDAQ

NASDAQ Global Market • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score

34/100

1/6 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

AcelRx Pharmaceuticals, Inc. (ACRX) .

本页证实的标准:

VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。

SharesGrow 综合评分： 33/100 其中 1/7 项标准通过。

SharesGrow 7-Criteria Score

34/100

SG Score

View full scorecard →

—

价值

N/A

No coverage

未來

40/100

Analyst consensus

→ Forecast

✗

过去

25/100

→ Income

✓

健康

100/100

Debt-to-Equity & liquidity

→ Health

✗

护城河

15/100

→ Income

✗

成长

15/100

→ Income

✗

收入

10/100

→ Income

估值概览 — ACRX

估值倍数

P/E (TTM)0.0

前瞻 P/EN/A

PEG 比率N/A

前瞻 PEGN/A

P/B 比率0.00

P/S 比率1,302.61

EV/EBITDA0.0

每股数据

EPS (TTM)$-0.34

每股账面价值$0.00

每股营收$0.00

每股自由现金流$0.00

收益率与内在价值

盈利收益率N/A

股息收益率0.00%

EPS：实际 vs 预期

P/E Ratio & Earnings Yield

每股收益 (EPS) 历史

Year	EPS（稀释）	营收	净利润	净利润率
2016	$-19.05	$17.36M	$-43.16M	-248.6%
2017	$-21.97	$8M	$-51.51M	-644.3%
2018	$-16.20	$2.15M	$-47.15M	-2192%
2019	$-13.40	$2.29M	$-53.24M	-2325.9%
2020	$-9.40	$5.42M	$-40.38M	-745.6%
2021	$-5.86	$2.82M	$-35.1M	-1245.5%
2022	$5.72	$1.77M	$47.76M	2696.5%
2023	$0.00	$651K	$-10.29M	-1580.2%
2024	$-0.87	$0.00	$-13M	-
2025	$-0.34	$28K	$-14.29M	-51035.7%